Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in Bernese Mountain Dogs and Flatcoated Retrievers. by Erich, Suzanne A et al.
1	
	
Morphological Distinction of Histiocytic Sarcoma from Other Tumor Types in 
Bernese Mountain Dogs and Flatcoated Retrievers 
 
Suzanne A. Erich1, Fernando Constantino-Casas2, Jane M. Dobson2 and Erik Teske1 
 
1Department of Companion Animals, Faculty of Veterinary Medicine, Utrecht 
University, Utrecht, the Netherlands; 
2Department of Veterinary Medicine, University of Cambridge, Cambridge, UK 
 
Correspondence to: Erik Teske, Department of Companion Animals, Faculty of 
Veterinary Medicine, Utrecht University, Yalelaan 108, PO-box 80.154, 3508 TD, 
Utrecht, NL.  E-mail: e.teske@uu.nl 
 
Running title: Morphological Characterization of Histiocytic Sarcoma 
 
Key Words: Canine, histiocytic sarcoma, histo(patho)logy, cytology, 
immunohistochemistry, Bernese Mountain Dog, Flatcoated Retriever, comparative 
pathology. 
 
Experimental Study 
Date of Submission: 
  
2	
	
Abstract. Background/Aim: Histiocytic sarcoma (HS) represents a group of  malignant 
canine tumors to which Bernese Mountain Dogs (BMD) and Flatcoated Retrievers 
(FCR) are predisposed. The differential diagnosis for HS is broad, encompassing  
round cell tumors, sarcomas and other histiocytic diseases. the aim of this study was 
to establish morphological and  immunohistochemical (IHC) criteria for routine use on 
formalin-fixed, paraffin-embedded  samples and cytological smears for the 
recognition and differentiation of canine HS and its subtypes. Materials and Methods: 
Retrospectively, tumor sections were reviewed from 449 BMD and 380 FCR with 
confirmed or suspected HS, other histiocytic conditions, or a disease of the 
differential diagnosis of HS. Results: In a large proportion of the cases, 47.5% for 
histology and for 46.3% cytology, the initial diagnosis was changed after the revision 
process. A large variation in morphological features of HS was observed in this study, 
making the existence of several subtypes  in dogs also very likely. Furthermore, the 
different percentage of morphological features between BMD and FCR indicates the 
different mixture of cell type origins resulting possibly from genetic or environmental 
differences at the onset of HS in those breeds. Conclusion: This study stresses the 
value of a strictly applied and standardized scoring system for microscopic evaluation 
of tumor sections and smears, and the implementation of review and revision of 
pathological diagnoses.  
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Histiocytic sarcoma (HS), formerly known as malignant histiocytosis (MH), is one of 
the most aggressive and incurable tumors in dogs (1). The Bernese Mountain Dog 
(BMD) and Flatcoated Retriever (FCR) are predisposed to these tumors, in which it is 
a major cause of death (2). The dog, especially BMD and FCR, is also recognized as 
an excellent animal model for spontaneously occurring histiocytic tumors (3, 4).  
 The differential diagnoses for HS are many and include not only almost the 
entire spectrum of poorly differentiated round cell tumors, but also other histiocytic 
diseases such as reactive cutaneous/systemic histiocytosis (CH/SH), 
hemophagocytic syndrome, immune-mediated hemolytic anemia, and granulomatous 
inflammation (1,5-9).   
 Despite the fact that several attempts have been made to designate specific 
criteria for the diagnosis for human and canine HS, routine implementation of these 
criteria in veterinary medicine still appears to be unsatisfactory due to a broad array 
of opinions and poor definition and understanding of the different disease entities (1, 
10). 
 In contrast,  in humans, several subtypes of histiocytic tumor have been 
identified (11,12) and the term HS in humans now mainly indicates the macrophage 
subtype only. Further subtypes of histiocytic tumors in humans are Langerhans cell 
histiocytosis (LCH) and Langerhans cell sarcoma (LCS), follicular dendritic cell 
sarcoma (FDCS),  interdigitating dendritic cell sarcoma (IDCS), undetermined 
dendritic cell sarcoma (DCS NOS),  and plasmacytoid dendritic cell tumor (PDCT) 
(11-14).  
 Histiocytic proliferations in the dog are subclassified as: non-neoplastic 
diseases e.g. granulomatous inflammation, and reactive and systemic histiocytosis;  
benign tumors, i.e. histiocytoma, and malignant tumors, the histiocytic sarcomas (15). 
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This latter group is subdivided into localized and systemic histiocytic sarcomas and 
the splenic hemophagocytic sarcoma (HHS). Different histiocytic subtypes are 
thought to be the origin of these different histiocytic diseases (1) and can be 
identified with a panel of cluster of differentiation (CD) markers on fresh material. 
However, for routine classification on formalin-fixed, paraffin-embedded (FFPE) 
samples, unfortunately no definitive immunohistochemical (IHC) panel is available 
yet.  
 The terminology  and diagnostic criteria applied to this group of diseases has 
evolved over the past 20 years.  Reports of canine HS in the literature use a variety 
of different inclusion criteria for HS, some of which are now outdated, and many did 
not utilize IHC to verify the histiocytic nature of the tumors or even included dogs as 
HS case without any pathological examination (16). None of the reports included a 
large number of dogs of the same breed. In addition, in recent years, HS seems to 
have become a synonym for any poorly differentiated round-polygonal cell tumor. 
This makes it difficult to determine specific morphological and IHC criteria to be used 
by pathologists for diagnosis of HS and thus the diagnosis of HS and HHS remains a 
matter of some debate. 
 Therefore the goal of this study was to establish morphological and IHC 
criteria, for routine use on FFPE samples and cytological smears, for the recognition 
and differentiation of canine HS and its subtypes within the wide spectrum of 
histiocytic diseases and other malignant tumors in a  large number of dogs of the two 
breeds particularly affected by canine HS. 
 
Material & Methods 
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Selection of candidates for inclusion. Cases for potential inclusion into the study  
were BMDs and FCRs with the histological and/or cytological diagnosis of a 
(suspicion of) HS/MH, with (a suspicion of) one of the other histiocytic diseases or a 
disease of the differential diagnosis of HS or HHS of dogs and humans. Cases  were 
collected from the Netherlands, Germany, Belgium, Switzerland and the United 
Kingdom (FCRs only) using database searches for the diseases listed above  in the 
Veterinary Pathological Diagnostic Centre (VPDC) and the University Veterinary 
Diagnostic Laboratory (UVDL) of the University of Utrecht (NL), Veterinary Specialist 
Centre The Wagenrenk (Wageningen, NL), Valuepath (Hoensbroek, NL), Vetipath 
(Westervoort, NL), and the Veterinary Pathology Service of the University of 
Cambridge (UK). Start of the selection period was dependent on the start of 
digitalization of the database of each laboratory and varied from 1989 to 2004  and 
took place until July 2011.  
 Veterinary records of the candidates were collected from the associated 
veterinarian. Dogs were only included in this study when being a family-owned 
purebred BMD or FCR and complete clinical and pathological reports and associated 
samples were available for review. Pedigree data were collected from the owner and 
verified using the digital databases of BMDs and FCRs of the Dutch Kennel Club 
(Amsterdam, The Netherlands). 
 
Specimens. Nine hundred and eighteen histological  FFPE tissue samples were 
obtained from 894 cases (493 BMD; 401 FCR). All of the 918 FFPE tissue samples 
were sectioned at 4-6 μm, mounted on slides and stained with hematoxylin and eosin 
(H&E) and with IHC markers. 
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 Four hundred and thirty-two  cytological samples were obtained from 396 
cases (255 BMD; 141 FCR), of which 220 were accompanied by  pathological 
specimens. Cytological specimens consisted of fine-needle aspiration biopsy smears 
and were stained with May-Grünwald Giemsa and a few selected cases also with 
immunocytochemistry for CD3 (Dako CD3 Clone F7.2.38, Dako Denmark A/S, 
Glostrup, Denmark)  and CD79a (Dako CD 79acy Clone HM57; Dako Denmark A/S, 
Glostrup, Denmark) if differentiation from lymphoid tumors was necessary.  
 
IHC procedure. Due to a lack of specific IHC stains that accurately separate different 
types of sarcomas, a selection of antibodies was used to differentiate between 
specific diagnoses. In order to indicate a histiocytic origin, all histological samples 
were also stained and evaluated with the CD18 antibody (CA16.3C10, IgG1, anti-
canine mouse monoclonal; P.F. Moore, University of California,  Davis, CA, USA), 
which is a leukocyte marker and is able to differentiate neoplasms of leukocyte origin 
from other types of sarcomas.  
 Other antibodies used, if needed to further characterize the tumors, were 
against CD3 (CMC 10317020, polyclonal; Cell Marque, Rocklin, California, USA), a 
marker for T-cell lymphoma; CD79a (Clone HM57, monoclonal; Dako Cytomation, 
Glostrup, Denmark), a marker for B-cell lymphoma; melan-A (Clone A103, 
monoclonal; Dako), a highly specific and low sensitive melanocytic marker; S-100 
(Dako Z0311), a non-specific marker of melanocytic tumors and peripheral nerve 
sheath tumors; vimentin (Clone V9; Dako), a general mesenchymal cell marker; 
Cytokeratin (Clones AE1/AE3; Dako), an epithelial cell marker; NSE (Clone E27, 
Neomarkers/Labvision); Chromogranin A; smooth muscle actin (SMA Clone A4; 
Dako); α1-antitrypsin; MAC387 (NCL-MAC387; Novocastra) for identification of 
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macrophages; E-cadherin, periodic acid Schiff for detection of polysaccharides; Van 
Giesson; Ziehl Neelsen; Lysozyme (A 0099; Dako) for identification of histiocytic and 
myeloid neoplasms; Von Willebrand factor (A 0082; Dako) for identification of 
neoplasms of endothelial origin; actin (Clone HHF35; Dako), which labels myocardial, 
skeletal and smooth muscle cells as well as myoepithelial cell; and toluidine blue for 
identification of mast cell tumors. 
 Antibody to CD11d /CD45 (Professor P.M. Moore) was used, if needed, to 
identify hemophagocytic HS. Unstained histopathological slides of 14 cases in 
Utrecht clinically and morphologically highly suspicious of HS but CD18-negative 
were sent to Professor P.M. Moore. These slides were added to a selection of 12 
cases diagnosed as HS, other histiocytic diseases and other tumors. These were 
mixed and sent to Professor P.M. Moore without associated diagnoses, to test for 
diagnostic agreement and supplementary immunohistochemistry, including CD18 
with an alternative antigen retrieval method, CD45, CD11d and E-cadherin.  
 
Pathological revision. Revision of the histological samples was carried out by a 
veterinary pathologist (F.C.C.) and that of the cytological samples by a veterinary 
cytologist (E.T.).  
 The risk of bias was minimized by several measures: the first diagnosis was 
not known to the revising pathologist/cytologist; the diagnosis was only made with the 
help of a scoring system based on standardized morphological criteria combined with 
IHC; all IHC was performed in the same laboratory at the same time period with the 
same antibody and procedure.  If any doubt existed, only a probable diagnosis was 
reported,  decision by consensus was undertaken for agreement on difficult cases 
and for the determination of final morphological criteria for the diagnosis of HS.  
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HS inclusion criteria and morphological evaluation system. Pathological criteria for 
initial selection as candidates for inclusion into the study as possible HS cases were 
derived from literature (1,17). IHC criteria for possible HS cases were CD18-
positivity, while staining negative with other antibodies indicating other tumor types.  
 All cases were evaluated for cellular and nuclear shape (predominantly round 
or polygonal, or mixed round and polygonal), presence or absence of spindle cells, 
multinuclearity, whorling, phagocytosis, vacuolization, necrosis, hemorrhage, 
extramedullary hematopoiesis, mineralization, tissue reaction, (abnormal) mitotic 
figures, affected tissue type and invasion in surrounding tissues, blood and lymph 
vessels and sinusoids, and inflammatory response, including type of inflammatory 
cells. For this, representative parts of the slides were identified at ×100 magnification 
and 10 fields were evaluated at ×200 magnification.  
 
HHS inclusion criteria. Provisional pathological criteria for inclusion in the study as 
possible HHS cases were derived from Moore et al. (8). Dogs were selected if the 
histiocytic tumor cells showed phagocytosis of erythrocytes, a diffuse pattern of 
tissue involvement, with preferably intra-sinusoidal (liver/lymph nodes) and 
intravascular spread and involvement of splenic red pulp, while encroaching on the 
white pulp with only sparse lymphocytic infiltration. Involvement of the spleen or liver 
increases the likelihood of HHS. If tested, CD11d positivity and Coombs negativity 
were a requisite, while responsive anemia, thrombocytopenia and hypoalbuminemia 
were further supportive of HHS. 
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Statistical analysis. To test for significant differences between cyto-
histomorphological characteristics between BMD and FCR dogs, chi-square tests 
were performed. Differences with p-values of less than 0.05 were considered to be 
significant. 
 
Results   
Initial diagnoses. A total of 1009 histology records (526 BMD and 483 FCR) were 
identified, of which 918 samples from 894 cases (493 BMD and 401 FCR) were 
available. Of these 894 cases, 829 were diagnostic (449 BMD and 380 FCR). A total 
of 504 cytology records (337 BMD and 167 FCR) were identified, of which 432 
samples from 396 cases (255 BMD and 141 FCR) were available. Of these 396 
cases, 343 were diagnostic (223 BMD and 120 FCR). Of these cytology cases, no 
histology was available in 176 cases. Results of initial histological and cytological 
diagnoses are listed in Table I and II, respectively.  
 Of 654 dogs (365 BMD and 289 FCR) with the diagnosis of HS, it was 
possible to further sub-classify these into localized HS (n=318) and disseminated HS 
(n=336). Localized HS was significantly (p<0.001) more frequent in FCR (60.6%) 
than in BMD (39.2%). 
 
Revision. Histology: During revision, including the IHC, the diagnosis of 435 out of 
the 829 (47.5%) diagnostic histological cases changed towards another tumor type or 
disease category. The diagnosis changed significantly more often (p=0.032) in FCR 
(201/380) than in the BMD (203/449). In all cases, immunostaining for CD18 was 
performed and in 421 cases, additional staining for CD3 and CD79a was performed. 
Concerning the use of CD3 and CD79a, besides CD18, the cases with HS 
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morphology were all consistently CD18+CD3−CD79a−, while the cases with ML 
morphology were consistently CD18−CD3+/− CD79a+/− and the cases with other 
tumors were also CD3−CD79a−. 
 Of the diagnostic histological cases which were first only suspected of HS, 112 
cases (74.6%) were confirmed as HS, while 39/301 cases (12.9%) became uncertain 
or were classified as another tumor or inflammation. No significant difference was 
found between BMD and FCR. A large proportion (34.6%) of the CH/SH were 
reclassified as HS on revision, while none of the malignant fibrous histiocytoma 
(MFH) were reclassified as MFH, and 13/15 became HS. MFH was significantly more 
often diagnosed initially in FCR (n=11) than in the BMD (n=4). A large proportion of 
the sarcomas (74/139; 53.2%) were classified as HS on revision, as were the 
synovial cell sarcomas (9/15; 60%). Sarcomas which turned out to be HS were 
significantly (p<0.001) more often seen in the FCR cases first diagnosed with an 
undifferentiated/anaplastic or spindle cell sarcoma (64/97; 65.9%) than in the BMD 
(10/42; 23.8%). Based on the clinicopathological characteristics and CD11d 
immunostaining, hemophagocytic HS (HHS) was diagnosed in at least 12.3% (45 out 
of 365) of the BMD and in 2.4% ( seven out of 289) of FCR.  
 The slides of 26 cases of this study (12 FCRs and 14 BMDs) were sent to Dr. 
P.F. Moore in Davis (CA, USA) to test for diagnostic agreement. All 14 cases (six 
FCR; eight BMD) which were morphological highly suspicious of HS but CD18-
negative in Utrecht, turned out to be HS cases according to P. F Moore. There was 
also full agreement on the diagnosis of the 12 cases (six FCR and six  BMD) with 
HS, other histiocytic diseases and other tumors, which were sent to test for 
diagnostic agreement and supplementary immunohistochemistry, including CD45, 
CD11d and E-cadherin. 
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 Cytology: During revision, the diagnosis of 159 out of the 343 (46.3%) 
diagnostic cytological cases changed to another tumor type or disease category. 
These percentages were not significantly different between BMD and FCR. Of the 
diagnostic cytological cases which were first only suspected to be HS, 80 cases 
(53.3%) were confirmed as HS, while 27/162 cases (16.7%) became uncertain or 
were classified as another tumor type or inflammation. 
 
HS morphology. When results of histology and cytology are combined, 654 cases of 
HS were diagnosed (365 BMD and 289 FCR). Results of morphological scoring for 
BMD and FCR with HS on histology slides or cytology slides, when available, on 
cellular and nuclear shape, presence or absence of spindle cells, multinuclearity, 
phagocytosis, vacuolization, necrosis, hemorrhage, extramedullary hematopoiesis, 
mineralization, tissue reaction, (abnormal) mitotic figures, artifacts including type of 
artifacts, affected tissue type and invasion in surrounding tissues, blood and lymph 
vessels and sinusoids, and inflammatory response, including type of inflammatory 
cells, are listed in Table III and Figure 1.   
 Several significant differences of HS morphology were found between BMD 
and FCR. Concerning the cell shape, a higher percentage tumors with only polygonal 
cells were seen  in FCR than in BMD (p<0.001), while in BMD, a higher percentage 
with only round-oval cells were seen (p=0.02). When polygonal cells were seen in 
BMD, this was more often in combination with round cells than in the FCR (p<0.001). 
The presence of polygonal cells was not significantly different for localized or 
disseminated HS. A higher percentage of cases with spindle cells was seen in the 
FCR compared to the BMD (p=0.004), but also in localized HS (31.4%) compared to 
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disseminated HS (15.9%) (p=0.001).  Whorling (n=5) was a rare finding and 
exclusively seen in BMD and mostly (4/5) in localized HS. 
 Both in FCR, as well as in localized HS, less phagocytosis by tumor cells 
(p<0.001) and less multinuclearity (p=0.016 and p<0.001, respectively) were seen. 
The inflammatory component in BMD more often contained infiltrating small 
lymphocytes than in FCR (p=0.03), not only solely (p=0.036) but also in combination 
with neutrophils (p<0.001). In BMD, a higher percentage with intravascular (p<0.001) 
and intrasinusoidal (p<0.001) tumor cells was seen. A higher percentage of FCR 
cases with necrosis was seen (p<0.001), while in BMD, a higher percentage with 
extramedullary hematopoiesis was seen (p<0.001). 
 Of the HS cases, 45 BMD and eight FCR  met the inclusion criteria and were 
identified as being of the HHS subtype.  
. 
Discussion  
In the present study, a large series of histiocytic sarcomas and its differential 
diagnoses in BMD and FCR were selected based on their initial diagnosis during a 
routine examination by a clinical or anatomic pathologist. It was found that a large 
proportion of these initial diagnoses, 47.5% and 46.3% for histology and cytology, 
respectively, were changed by the revision process to different diagnoses, with the 
help of a scoring system on several standardized morphological criteria combined 
with IHC. In the group of sarcomas, it was not always possible in this study to further 
characterize them after being excluded as of histiocytic origin. In an earlier 
comparison by Regan et al. of first and second opinion histopathology of 430 tumors 
in dogs, 30% of diagnoses disagreed,  with 17% having an impact on therapy or 
prognosis, with an especially high percentage among mesenchymal tumors (18).  In 
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their study, four tumors (two sarcomas, one round cell tumor and one plasma cell 
tumor (PCT),became HS and two HS cases became another diagnosis (one T-cell 
lymphoma and one melanoma). This stresses the need for high and uniform 
certification standards and standardized diagnostic criteria and workup for veterinary 
clinical and anatomic pathologists, and that review and (randomized) second opinion 
pathology/cytology and  revision is recommended. Complete clinical information 
could further help to increase diagnostic accuracy (18). In human medicine, second-
opinion tumor histopathology is already recommended as standard practice, before 
treatment is requested, to avoid unnecessary or inappropriate treatments. Although 
in humans the discrepancy rate is relatively small (1.4-5.8% changes) (19,20), it is 
high enough that the Association of Directors of Anatomic Surgical Pathology has 
recommended institutional consultation as a standard practice (21).  
 Archiving of samples and good accessibility and maintenance of the archive, 
besides digital documentation of demographic, clinical and pathological information, 
linked with the samples, both easily traceable with a search engine, turned out to be 
paramount for enabling the contribution of samples to research. In this context, the 
great advantage of histology over cytology is that the original samples can remain in 
the possession of the laboratory, while many sections of the tissue blocks can be cut 
and used in research projects. In this study, histological needle core biopsy (Tru-cut) 
and other biopsies with a small width (<2 mm) were only assessable for a limited 
number of the morphological features. This resulted in a less reliable morphological 
diagnosis, while the performance of IHC is often less reliable in such small samples 
due to false-positive edge staining. Therefore taking such small biopsies is 
discouraged and surgical biopsies are highly recommended, which was also already 
concluded in human pathology (22). 
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 Although the differential diagnosis of a sample suspected of being a malignant 
tumor, with a possibility of HS, can already be narrowed down with morphological 
examination with strict differentiating morphological criteria only, all histological 
samples were also stained and evaluated with the CD18 antibody, as an extra 
confirmation of the leukocyte  origin of tumor cells. CD3 and CD79a should be 
added, as in this study morphology alone was also insufficient to differentiate HS 
from ML. A fair proportion of ML and HS switched from diagnosis between first and 
second evaluation. In order to indicate the macrophage origin of the HHS subtype, 
CD11d staining was helpful.  
 Some cases of HS in our study had weak or negative staining for CD18. 
Absence, weak or variable IHC staining intensity can be caused by the formaldehyde 
of the FFPE procedure.  Formaldehyde makes recognition of antigens difficult, and 
overfixation with this preserving agent can result in detection failure (or only weak 
reaction) (23). Differences in the degree of differentiation of the histiocytic tumor cells 
can result in different intensity of staining within and between cases (17). Variability 
in staining intensity for lysozyme in MH is related to the degree of anaplasia of the 
neoplasia (7,17). 
 Considering the fact that a large proportion of diagnoses were changed during 
the revision process, it is important to identify the cyto-/histomorphological 
characteristics of histiocytic sarcomas. Therefore, in the present study these aspects 
of histiocytic sarcomas were studied in 654 unique cases of two different predisposed 
breeds, BMD (n=365) and FCR (n=289). The systematic scoring of the morphological 
characteristics was performed on both histology and cytology slides, when both 
available, or on one of them. Although the tumors in both breeds had several 
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common characteristics, several significant differences of HS morphology were found 
between BMD and FCR (Table III). 
 When looking at the morphology of the tumor cells the majority of cells were 
either round-oval or polygonal (BMD) or polygonal only (FCR). Round-polygonal cells 
have been reported before in canine HS (9) and are also the main cell type in human 
HS (10). Polyhedral, as used in the canine literature by Nakayawa et al. (13), seems 
to be a less accepted term and polygonal is preferable in the context of uniform 
terminology. Spindle cells were seen in BMD but significantly more often in FCR. 
Most likely this is related to the more common localized HS found in FCR. Both in our 
study, as well as a earlier report (24), spindle cells were more often seen in this 
localized form compared to the disseminated HS. Spindle cells have been reported in 
canine HS before, but only in combination with round-oval cells (1, 24-28). This 
makes this study the first report of HS cases with spindle cells only. Spindle cells are 
also reported in human histiocytic tumors. When spindle cells are present in humans, 
most cases  turns out to be interdigitating dendritic cell sarcoma (IDCS) (29,30) or 
follicular dendritic cell sarcoma (FDCS) (31), especially when the presence of spindle 
cells is prominent and the formation of whorls is seen. Whorling is also reported in 
human IDCS (29,32) and FDCS (31), but never before in canine HS although the 
frequency was low and it was only seen in BMD. These canine cases with spindle 
cells (54 BMDs, 68 FCRs) may denote a yet unknown subtype of canine histiocytic 
tumors, possibly resembling IDCS and FDCS in humans. Unfortunately, no canine 
immunohistochemical markers are available yet to definitively characterize those 
possible subtypes. Further research is warranted. 
 Phagocytosis of erythrocytes and leukocytes by the tumor cells was 
significantly more often seen in BMD than in FCR, but this could have been related to 
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the more frequent presence in disseminated HS. This has been reported before in 
canine HS (1, 6, 7, 28, 33-39) and is also often seen in human HS, sometimes 
simultaneously with spindle cells (40, 41). In addition, extramedullary hematopoiesis 
was seen more often in BMD than in FCR. This could well have been related to the 
higher amount of erythrophagocytosis seen in HS in BMD. As hematological data 
were missing in this study, a correlation with anemia could not be established. 
Extramedullary hematopoiesis is also reported in canine HHS (8). Vacuolization of 
the cytoplasm of tumor cells was seen in some 14% of the cases, equally distributed 
among the BMD and FCR. In earlier studies, the percentage of tumor cells showing 
vacuolization in both BMD and FCR was higher (1, 7, 33, 34, 38, 39, 42). However, in 
human HS, this is reported at  a much lower percentage, comparable to the results in 
our study.  
 Multinucleated giant cells are common in canine HS (15,33), especially in the 
disseminated form. In humans, multinucleated giant cells are  less frequently present 
in HS (43), as well as in IDCS (13), FDCS (44) and indeterminate DCS (45), which 
may  imply a more malignant nature of HS in canines. The characteristic kidney-
shaped nuclei have also been reported before in canine HS (33, 39, 46) and in 
human HS (47) and IDCS (14). Indentations of the nucleus have been reported in the 
canine literature (1, 7, 24, 26, 28) as well as in human HS (41) and IDCS (48), and a 
combination of indentations, grooves or folds in human HS (43, 49), IDCS  (14) and 
LCH (50).  This indicates that a canine subtype comparable to human LCH/LCS may 
also exist. An eccentrically located nucleus was reported in canine HS (6, 37, 51) and 
in human HS (41) and IDCS (14). Further research will shed light on possible 
similarities among human and canine histiocytic tumor subtypes. 
 An inflammatory infiltrate of lymphocytes was seen in 21.8% (FCR) to 29.3% 
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(BMD) of the cases. The infiltration of lymphocytes only has been reported before in 
canine HS (1, 6, 20, 24, 28, 39, 52), but inflammatory patterns of neutrophils only 
(34), a combination of lymphocytes and plasma cells (25),  of lymphocytes and 
neutrophils (7), of neutrophils and eosinophils (33), and of lymphocytes, plasma cells 
and neutrophils (1, 26, 25, 51) have also been reported. The difference between 
BMD and FCR with regard to inflammatory pattern, with BMD having more often 
small lymphocytes, has not been reported before as far as we are aware.  
 Invasive behavior of the tumor cells, both in blood and lymph vessels and in 
liver and lymph node sinusoids, was sometimes noted (up to 7.1%) in BMD, but was 
almost absent from FCR. This invasive behavior was exclusively found in 
disseminated HS. A sinusoidal pattern has been recognized before in canine HS in 
lymph nodes (37) and in the liver including invasion of the portal areas (28), and has 
been associated with the HHS subtype (8). It is also reported in human HS (54, 55). 
Red pulp and intravascular invasion with phagocytosis is recognized in canine HS (7) 
and HHS (8), and in human HS (55). Necrosis was more often seen in FCR than in 
the BMD and may indicate a higher malignancy/faster growing tumor than in the 
BMD. 
 Different morphological characteristics in different organs within one case were 
seen in this study and have been reported before (56). Metastatic tumor cells seem 
to first disseminate from the early primary lesion and then acquire additional genetic 
defects and often exhibit properties different from the cells of the primary lesion (57). 
Macrophage-dendritic cell-HS-hybrids are possible in dogs, but tissue infiltration is 
discrete by subtype (8). Further research is needed.  
 It can be concluded that canine HS, including its subtypes, can be recognized 
morphologically by a mostly easily harvested dense pleomorphic cell proliferation of 
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large round-oval to polygonal, sometimes spindle-shaped, cells with abundant, often 
vacuolated, cytoplasm. Anisocytosis and anisokaryosis can be marked and the tumor 
cells have large nuclei, which are round, indented, lobulated, doughnut- or kidney-
shaped, with one or several nucleoli, and often have abnormal mitotic figures. 
Neoplastic bi- or bizarre multinucleated giant cells, up to 160 μm, often accompany 
the tumor. Vacuolization and phagocytosis of erythrocytes and other (tumor)cells is 
often seen, but the intensity may vary. A mostly sparse infiltration of inflammatory 
cells is possible, consisting of small lymphocytes, plasma cells, neutrophils, 
eosinophils and/or reactive macrophages. Additionally, in the histological samples, a 
poorly demarcated mass can be seen, with invasion of surrounding tissue and of 
blood and lymph vessels, sinuses of lymph nodes or sinusoids of the liver, which is 
easily missed. Tumors with spindle cells can show whorling and the tumor is often 
accompanied by variable amounts of necrosis, hemorrhage and extramedullary 
hematopoiesis and sometimes thrombi.  
 The large variation in morphological features that has become visible in the 
population of BMDs and FCRs in this study, makes the existence of several subtypes 
of canine HS very likely. These subtypes assume there are different cells of origin, 
different routes of differentiation or different involved genetic causes. This underlines 
the importance of further research on subtypes of HS because those subtypes likely 
entail different prognoses and different therapies. From this comparison with canine 
and human literature about histiocytic tumors, it can be concluded that it is likely that 
canine counterparts exist of human (macrophage) HS,  FDCS, IDCS and LCH/LCS.  
 Different percentages of cellular features in the BMD and FCR (Table III) may 
indicate a different mixture of histiocytic cell type origins in FCR and BMD, resulting 
possibly from partial genetic or environmental differences at the onset of HS (4, 58). 
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The breed-associated clinical features, such as differences in median age at 
diagnosis and localization of primary tumor, and a small number of DNA copy number 
aberrations  between BMD and FCR also indicate differences in disease subtype 
between the two breeds (4). Different authors use different names to describe cell 
types. In order to come to a uniform report on HS,a uniform terminology of cell types 
has to be accepted. 
  HHS represents a distinct entity in the dog with distinctive clinicopathological 
features (15). Clinical and pathological findings which can indicate HHS are 
phagocytosing histiocytes, a diffuse pattern of tissue involvement, with preferably 
intra-sinusoidal (liver or lymph nodes) and intravascular spread and involvement of 
splenic red pulp, while encroaching on the white pulp with only sparse (T-cell) 
lymphocytic infiltration, extramedullary hematopoiesis, especially when the 
phagocytosis is prominent. Immunohistochemically, HHS cells typically have 
abundant and strong CD18 positivity (but this can be less intense in less 
differentiated tumors) (8) and, if tested, CD11d positivity and Coombs negativity as a 
requisite, while responsive anemia, thrombocytopenia and hypoalbuminemia are 
further supportive. When HS cases show these findings there is a high possibility that 
these are of the HHS subtype (15). In the present study, we found the percentage of 
hemophagocytic HS in BMDs to be at least 12.3% (45 out of 365) and in the FCR at 
least 2.4% (seven out of 289). The use of CD11d could be helpful for the diagnosis of 
HHS, but seems not to be essential for diagnosis because morphology and clinical 
symptoms of HHS seem to be characteristic, in other words they can differentiate 
HHS cases from classic HS cases. In addition,  CD11d is not specific for HHS. When 
looking at the human HS cases for which phagocytosis was explicitly reported, the 
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morphological characteristics of canine HHS were also found in the human 
counterpart (55). 
 Morphological and IHC differentiation of HS and other malignant tumors and 
histiocytic diseases is possible and feasible on routine FFPE histological and 
cytological samples. Therefore strict and specific criteria and a standardized workup 
are essential. Differences in cellular features between humans and dogs and 
between BMD and FCR  may indicate pathophysiological species differences and a 
different mixture of histiocytic cell type origins in FCR and BMD possibly results from 
partial genetic or environmental differences at the onset of HS. Furthermore, the 
implementation of revision and consensus of pathological diagnoses is 
recommended. 
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Table I. Initial diagnoses and results of revision histopathology in 449 Bernese Mountain Dogs and 380 Flatcoated Retrievers. 
 
 After revision, n 
Before 
revision, n 
HS Susp 
HS 
CH/SH ML PCT Sarc OSA HSA SCS GIST Amel Carc Undiff CCH Benign Inflam Total 
HS 262 3 4 4  16  3 2  1 1  1  4 301 
Susp HS 112 9 9 2 1 11 1 1   2  1   1 150 
CH/SH 18 3 15   4   2    1   9 52 
MFH 13     1  1         15 
ML 5   26  3       1 1   36 
PCT 3 1 1  6 5      1     17 
Sarc 74 2 2 3  46 1  1 1  1 2 1 2 3 139 
OSA 1     4 8  1        14 
HSA 3     1  43        1 48 
SCS 9 1    2 2  1        15 
Amel 2   1  2     1      6 
Carc 3 1    1      1 1    7 
Undiff 2 1              2 5 
CCH 2   1  3        3   9 
FHNod 1                1 
Inflam 1 1 5 1  1  1        4 14 
Total 511 22 36 38 7 100 12 49 7 1 4 4 6 6 2 24 829 
 
Amel: Amelanotic melanoma; Benign: benign tumor; Carc: carcinoma; CCH: canine cutaneous histiocytoma; CH/SH: 
cutaneous/systemic histiocytosis; FHNOD: fibrohistiocytic nodule; GIST: gastro-intestinal stromal tumor; HS: histiocytic sarcoma; 
HSA: hemagiosarcoma; Inflam: (granulomatous) inflammation; MFH: malignant fibrous histiocytoma; ML: included as first diagnosis 
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are B-/T-malignant lymphoma and lymphosarcoma; OSA: osteosarcoma; PCT: plasma cell tumor; Sarc: undifferentiated sarcoma; 
SCS: synovial cell sarcoma; Susp HS: suspected HS; Undiff: undifferentiated tumors. 
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Table II.  Initial diagnoses and results of revision cytology in Bernese Mountain Dogs (n=223) and  Flatcoated 
Retrievers (n=120). 
 
  After revision  
Before revision HS Susp HS CH/SH ML    Sarc OSA Undif Amel? Carc Inflam IHA Total 
HS 135 19 1 1 3 2 1     162 
Susp HS 80 38 4 11 10  1 1  5  150 
CH/SH 2           2 
ML  1  3 1       5 
Sarc 3 4   6  1   2  16 
OSA     1       1 
Undiff            0 
Carc       1  1   2 
Inflam  3          3 
CCH     1       1 
IHA           1 1 
Total 220 65 5 15 22 2 4 1 1 7 1 343 
 Amel?: Suspected amelanotic melanoma; Carc: carcinoma; CCH: canine cutaneous histiocytoma; CH/SH: cutaneous/systemic 
histiocytosis; HS: histiocytic sarcoma; IHA: immune-mediated hemolysis of the spleen; Inflam: (granulomatous) inflammation; ML: 
included as first diagnosis are B-/T-malignant lymphoma and lymphosarcoma; OSA: osteosarcoma; Sarc: undifferentiated sarcoma; 
Susp HS: suspected HS; Undiff: undifferentiated tumors.
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Table III. Comparison of histiocytic sarcoma morphology in Bernese Mountain 
Dogs (BMD) and Flatcoated Retrievers (FCR) 
Compartment BMD (n=365 FCR 
(n=289) 
p-Value 
 n % n %  
Histiocytes      
     Morphology cells      
              Predominantly round 79 21.6 42 14.5 0.020 
              Predominantly polygonal     105 28.8 156 54.0 <0.001 
              Mixed round+polygonal 174 47.7 86 29.8 <0.001 
     Presence of spindle cells 54 14.8 68 23.5 0.004 
     Presence of whorling 5 1.4 0 0.0 0.070 
     Presence of multinucleated giant 
cells 
275 75.3 193 66.8 0.016 
Presence of aberrant nuclear 
shapes 
48 13.2 27 9.3 0.129 
     Cytoplasm      
              Presence of phagocytosis 98 26.8 32 11.1 <0.001 
              Presence of vacuolization 52 14.2 40 13.8 0.882 
Inflammation present 127 34.8 86 29.8 0.172 
     Type of inflammation      
              Small lymphocytes only 35 27.5 15 17.4 0.101 
              Plasma cells only 1 0.7 0 0.0 1.000 
              Neutrophils only 18 14.2 23 26.7 0.033 
              Eosinophils only 0 0 1 1.2 1.000 
              Macrophages only 1 0.7 0 0 1.000 
Small lymphocytes+plasma 
cells 
34 26.8 36 41.9 0.021 
              Small lymphocytes+plasma 
cells+ neutrophils 
10 3.9 5 5.8 0.786 
              Small 
lymphocytes+neutrophils 
26 20.5 4 4.6 0.001 
              Small 
lymphocytes+macrophages 
2 1.6 3 3.5 0.395 
Invasion of surrounding tissue 44 12.0 4 1.3 <0.001 
Presence of necrosis 169 46.3 232 80.3 <0.001 
Presence of hemorrhage 52 14.2 44 15.2 0.726 
Presence of extramedullary 
hematopoiesis 
30 8.2 5 1.7 <0.001 
Mineralization  1 0.3 0 0.0 1.000 
Aberrant shapes: Kidney-shaped, indented, lobulated or doughnut-shaped. EMH: 
extramedullary hematopoiesis. 
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Figure A: Fine-needle aspirate (FNA) of inguinal lymph node of Bernese Mountain 
Dog (BMD). Atypical mononuclear and multinucleated giant cells are present, 
withpathological mitosis, marked pleomorphism, anisokaryosis and vacuolated 
cytoplasm. May-Grünwald Giemsa (MGG), 500x. Figure B: FNA of spleen of BMD. 
Hemophagocytic histiocytic sarcoma, with a clear phagocytosis of mononuclear cells 
and erythrocytes. MGG, 1000x. Figure C: FNA of lymph node of Flatcoated Retriever 
(FCR). A clear anisokaryosis, as well as erythrophagocytosis are present. MGG, 
500x; Figure D: FNA of liver of BMD. Cytoplasmic extensions are visible as well as 
multinuclearity with aberrant nuclear shapes. MGG, 1000x. Figure E:  Cerebrum of 
FCR. Multifocally hemorrhage and spindle cells are present within the tumor mass. 
Hematoxylin and eosin (HE), 100x. Figure F. Spleen of BMD. In addition to the 
histiocytic tumour cells there are spindle cells with whorling present. HE, 400x.  
Figure G: Liver of  BMD. Tumor cells expand the liver sinusoids and portal vessels. 
HE, 100x. Figure H. Lung of BMD.  Bizarre multinucleated cell showing 
phagocytosis. HE, 400x. Figure I. Lung of BMD. The tumor cells, mononuclear as 
well as multinuclear, show strong expression of CD18. HE counterstain, 100x. 
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